申请人:THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SEC., DEPT. OF HEALTH AND HUMAN SERVICES
公开号:US20160083382A1
公开(公告)日:2016-03-24
A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of:
wherein X is N, C(OH), or CH;
Y is H or OH;
each of Z
1
-Z
5
is independently H or halogen;
R
4
is H, OH, NH
2
, NHR
8
, NR
8
R
9
or R
8
;
R
5
, R
6
, and R
7
is each independently H, halogen, OR
8
, R
8
, NHR
8
, NR
8
R
9
, CO
2
R
8
, CONR
8
R
9
, SO
2
NR
8
R
9
, or R
5
and R
6
together with the carbon atoms to which R
5
and R
6
are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and
R
8
and R
9
is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R
8
and R
9
together with the nitrogen to which R
8
and R
9
are attached form an optionally-substituted heterocycle.
本方法涉及在需要抑制药物耐药性HIV-1整合酶的主体中向其施用公式I的化合物的治疗有效量,或其药学上可接受的盐或酯,其结构为:其中X为N,C(OH)或CH;Y为H或OH;Z1-Z5中的每一个独立为H或卤素;R4为H,OH,NH2,NHR8,NR8R9或R8;R5、R6和R7各自独立为H,卤素,OR8,R8,NHR8,NR8R9,CO2R8,CONR8R9,SO2NR8R9或R5和R6与R5和R6附着的碳原子一起形成可选地取代的碳环或可选地取代的杂环;R8和R9各自独立为H,可选地取代的烷基,可选地取代的烯基,可选地取代的炔基,可选地取代的芳基,可选地取代的环烷基,可选地取代的环烷基,可选地取代的杂环,可选地取代的酰胺,可选地取代的酯,或R8和R9与R8和R9附着的氮一起形成可选地取代的杂环。